[go: up one dir, main page]

AR031288A1 - Metodos y composiciones para el tratamiento de enfermedades oftalmicas - Google Patents

Metodos y composiciones para el tratamiento de enfermedades oftalmicas

Info

Publication number
AR031288A1
AR031288A1 ARP010105085A ARP010105085A AR031288A1 AR 031288 A1 AR031288 A1 AR 031288A1 AR P010105085 A ARP010105085 A AR P010105085A AR P010105085 A ARP010105085 A AR P010105085A AR 031288 A1 AR031288 A1 AR 031288A1
Authority
AR
Argentina
Prior art keywords
compositions
treatment
methods
ophthalm
diseases
Prior art date
Application number
ARP010105085A
Other languages
English (en)
Inventor
Bender Hans-Markus Dr
Haunschild Jutta Dr
Wiesner Matthias Dr
Lang Ulrich Dr
Friedlander Martin Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29551237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR031288(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR031288A1 publication Critical patent/AR031288A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Métodos y composiciones para la profilaxis y/o el tratamiento de enfermedades oftálmicas resultantes de la angiogénesis en el ojo de un paciente usando antagonistas de los receptores de integrina alfavbeta3 y/o alfavbeta5. Las composiciones pueden ser nanopartículas y se administran mediante la inyeccion en la esclerotica del ojo.
ARP010105085A 2000-11-01 2001-10-31 Metodos y composiciones para el tratamiento de enfermedades oftalmicas AR031288A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24460600P 2000-11-01 2000-11-01
EP00124817 2000-11-14

Publications (1)

Publication Number Publication Date
AR031288A1 true AR031288A1 (es) 2003-09-17

Family

ID=29551237

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105085A AR031288A1 (es) 2000-11-01 2001-10-31 Metodos y composiciones para el tratamiento de enfermedades oftalmicas

Country Status (22)

Country Link
US (1) US7648959B2 (es)
EP (1) EP1381382B1 (es)
JP (1) JP5054274B2 (es)
KR (1) KR20030061390A (es)
AR (1) AR031288A1 (es)
AT (1) ATE415163T1 (es)
AU (2) AU2002238408B2 (es)
BR (1) BR0115077A (es)
CA (1) CA2427334C (es)
CZ (1) CZ20031332A3 (es)
DE (1) DE60136748D1 (es)
DK (1) DK1381382T3 (es)
ES (1) ES2315312T3 (es)
HU (1) HUP0302718A3 (es)
MX (1) MXPA03003741A (es)
NO (1) NO20031963D0 (es)
PL (1) PL204102B1 (es)
PT (1) PT1381382E (es)
RU (1) RU2003115425A (es)
SI (1) SI1381382T1 (es)
SK (1) SK5902003A3 (es)
WO (1) WO2002041910A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007770A (es) * 2002-02-14 2004-10-15 Merck Patent Gmbh Metodos y composiciones para tratamiento de enfermedades de los ojos.
DE10337863A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Verwendung von Chromen-4-on-Derivaten
EP2484365B1 (en) * 2004-06-04 2013-10-02 The Scripps Research Institute Compositions and method for treatment of neovascular diseases
BRPI0606172A2 (pt) * 2005-06-08 2009-06-02 Targegen Inc métodos e composições para o tratamento de distúrbios oculares
EP2214644B1 (en) * 2007-11-05 2013-03-20 Bausch & Lomb Incorporated Water-immiscible materials as vehicles for drug delivery
EP2706358A3 (en) 2008-12-23 2014-05-07 Merck Patent GmbH Biomarkers for inhibitors with anti-angiogenic activity
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
AU2013232300B2 (en) 2012-03-16 2015-12-17 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
PL3677252T3 (pl) 2012-03-19 2024-01-08 Cidara Therapeutics, Inc. Schematy dawkowania dla związków z klasy echinokandyn
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678168B1 (fr) * 1991-06-28 1993-09-03 Rhone Poulenc Rorer Sa Nanoparticules ayant un temps de capture par le dysteme reticulo endothelial allonge.
UA43823C2 (uk) 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
JP3309175B2 (ja) * 1996-03-25 2002-07-29 参天製薬株式会社 タンパク性薬物含有強膜プラグ
DE19613933A1 (de) 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
PL330241A1 (en) 1996-05-31 1999-05-10 Scripps Research Inst Methods of and compositions useful in inhibiting angiogenesis
US6559144B2 (en) 1997-02-13 2003-05-06 Merck Patent Gesellschaft Mit Bicyclic amino acids
DE19705450A1 (de) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
JP2000247871A (ja) * 1999-02-25 2000-09-12 Santen Pharmaceut Co Ltd 網膜または硝子体への薬物放出制御システム
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate

Also Published As

Publication number Publication date
PL360366A1 (en) 2004-09-06
ES2315312T3 (es) 2009-04-01
JP5054274B2 (ja) 2012-10-24
AU3840802A (en) 2002-06-03
KR20030061390A (ko) 2003-07-18
MXPA03003741A (es) 2003-07-28
AU2002238408B2 (en) 2006-12-21
US20060223746A1 (en) 2006-10-05
EP1381382A2 (en) 2004-01-21
ATE415163T1 (de) 2008-12-15
DK1381382T3 (da) 2009-02-02
HUP0302718A2 (hu) 2003-12-29
JP2004516254A (ja) 2004-06-03
CZ20031332A3 (cs) 2003-09-17
PL204102B1 (pl) 2009-12-31
PT1381382E (pt) 2009-03-03
US7648959B2 (en) 2010-01-19
NO20031963D0 (no) 2003-04-30
WO2002041910A2 (en) 2002-05-30
RU2003115425A (ru) 2004-11-27
EP1381382B1 (en) 2008-11-26
WO2002041910A8 (en) 2004-02-26
BR0115077A (pt) 2003-12-23
CA2427334C (en) 2013-06-11
HUP0302718A3 (en) 2011-03-28
DE60136748D1 (de) 2009-01-08
SK5902003A3 (en) 2003-08-05
WO2002041910A3 (en) 2003-11-20
SI1381382T1 (sl) 2009-04-30
CA2427334A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
AR048646A1 (es) Implante intraocular o intravitreo biodegradable que comprende un inhibidor de tirosina quinasa y un polimero biodegradable, metodo para producirlo y medicamento correspondiente
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
ATE418325T1 (de) Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon- acetonid und hyaluronsäure
MX2010012022A (es) Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular.
IL202851A (en) Use of a fragmented plasma protein protein preparation for the treatment of diseases related to ophthalmology
AR039511A1 (es) Agentes que regulan, inhiben, o modulan la actividad y/o la expresion del factor de crecimiento del tejido conjuntivo (ctgf) como unico medio para disminuir la presion intraocular y para tratar las retinopatias glaucomatosas/neuropatias opticas
HRP20050845A2 (en) Prostaglandin analogs as ep4 receptor antagonists
AR045039A1 (es) Dispositivo de administracion de drogas oftalmicas
AR034619A1 (es) Formulaciones de olopatadine para administracion topica
AR029941A1 (es) Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
WO2001030380A3 (en) Methods and compositions for treatment of keratoconus using protease inhibitors
AR045943A1 (es) Formulaciones de acetonido de triamcinolona y acetato de anecortave para inyeccion
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
AR041942A1 (es) Derivados de 10-oxa -1-aza-dibenzo [a,d] ciclohepteno-7-carboxilico como antagonistas ccr1 para el tratamiento de la enfermedad desmielinizante inflamatoria
AR009028A1 (es) Composiciones farmaceuticas, un procedimiento para preparar dichas composiciones y utilizacion de dichas composiciones en el tratamiento deenfermedades oftalmicas y metodos para tratar dichas enfermedades
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
ECSP055781A (es) Composiciones oftálmicas para el tratamiento de la hipertensión ocular
UY28202A1 (es) Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno

Legal Events

Date Code Title Description
FB Suspension of granting procedure